OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 141 filers reported holding OCULAR THERAPEUTIX INC in Q3 2021. The put-call ratio across all filers is 0.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $211,021 | -3.2% | 67,204 | +59.1% | 0.00% | – |
| Q2 2023 | $217,907 | -2.8% | 42,230 | -0.7% | 0.00% | – |
| Q1 2023 | $224,070 | -29.2% | 42,518 | -62.2% | 0.00% | -100.0% |
| Q4 2022 | $316,434 | +486.0% | 112,610 | +767.4% | 0.00% | – |
| Q3 2022 | $54,000 | -62.0% | 12,982 | -63.3% | 0.00% | – |
| Q2 2022 | $142,000 | +0.7% | 35,342 | +24.5% | 0.00% | – |
| Q1 2022 | $141,000 | -6.6% | 28,395 | +30.7% | 0.00% | – |
| Q4 2021 | $151,000 | -76.7% | 21,720 | -66.4% | 0.00% | -100.0% |
| Q3 2021 | $647,000 | -22.2% | 64,682 | +10.2% | 0.00% | 0.0% |
| Q2 2021 | $832,000 | -22.1% | 58,675 | -9.8% | 0.00% | -50.0% |
| Q1 2021 | $1,068,000 | +5.7% | 65,077 | +33.4% | 0.00% | 0.0% |
| Q4 2020 | $1,010,000 | +134.3% | 48,786 | -13.8% | 0.00% | +100.0% |
| Q3 2020 | $431,000 | -29.3% | 56,615 | -22.7% | 0.00% | 0.0% |
| Q2 2020 | $610,000 | +365.6% | 73,210 | +244.4% | 0.00% | – |
| Q3 2017 | $131,000 | – | 21,256 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 3,804,788 | $15,105,000 | 43.34% |
| Versant Venture Management, LLC | 2,215,384 | $8,795,074,000 | 2.90% |
| Opaleye Management Inc. | 1,900,000 | $7,543,000 | 2.09% |
| SV Health Investors, LLC | 628,236 | $2,494,000 | 1.46% |
| Endurant Capital Management LP | 716,124 | $2,843,000 | 1.12% |
| DELTEC ASSET MANAGEMENT LLC | 824,747 | $3,274,000 | 0.72% |
| NOTTINGHAM ADVISORS, INC. | 146,946 | $583,000 | 0.08% |
| Jump Trading, LLC | 39,255 | $156,000 | 0.05% |
| Man Group plc | 1,723,456 | $6,842,000 | 0.03% |
| JGP Global Gestao de Recursos Ltda. | 13,880 | $55,000 | 0.02% |